ZYUS Life Sciences Ships Medical Cannabinoid Oil Formulations For Distribution In Australia

ZYUS Life Sciences Inc., has completed its first international shipment of ZYUS’ first-generation cannabinoid oil formulations to the Australian medical cannabis market in preparation for the sales and distribution under Australia’s Therapeutic Goods Act special access and authorized prescriber scheme.

Through ZYUS’ Australian distributor, the company’s first-generation cannabinoid oil formulations will be accessible through approximately 4,300 pharmacies across Australia as physicians are introduced to ZYUS’ medical cannabinoid formulations.

Australia is the first international market to receive ZYUS’ first-generation cannabinoid oil formulations, with the company planning to export its first-generation medical cannabinoid products to additional markets in accordance with pharmaceutical distribution and sales agreements it currently has in place with various international distributors.

Three of ZYUS’ first-generation cannabinoid oil formulations, including Zylem 1:20 Oil (high CBD), Zylem 10:10 Oil (balanced CBD/THC), and Zylem 20:1 Oil (high THC), will be accessible through pharmacies across Australia as the company begins to scale its distribution network.

In addition to initiating distribution of ZYUS’ first-generation cannabinoid oil formulations in Australia, ZYUS continues to advance its research activities and has conducted its phase one human osteoarthritis pain evaluation clinical trial in Australia. The formulation being studied, Trichomylin softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate chronic pain and has the potential to be a safe and effective alternative to opioids – without the devasting addictive qualities. ZYUS’ second-generation drug product candidates, including Trichomylin softgels, will only be available to patients by prescription once it undergoes the required clinical trials and receives regulatory approval as a drug product.

Photo by Tim Foster on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsMarketsZYUS Life Sciences Inc.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.